nach oben

Drugs

Erschienen in:

01.08.2016 | AdisInsight Report

Obeticholic Acid: First Global Approval

verfasst von: A. Markham, Susan J. Keam

Erschienen in: Drugs | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Obeticholic acid (Ocaliva^TM) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. The drug is in preregistration for this indication in the EU. This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.

Intercept Pharmaceuticals. OCALIVA (obeticholic acid) US Prescribing Information. 2016. http://www.interconnectsupport.com/ocaliva_pi.pdf. Accessed 31 May 2016.

Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82.CrossRefPubMed

Dainippon Sumitomo Pharma Co L, Intercept Pharmaceuticals I. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals announce agreement to develop and commercialize obeticholic acid (INT-747) for chronic liver disease [media release]. 30 Mar 2011. http://www.interceptpharma.com.

Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals submits applications in the U.S. and Europe for marketing approval of obeticholic acid for the treatment of primary biliary cirrhosis [media release]. Jun 29 2015. http://ir.interceptpharma.com/releasedetail.cfm?releaseid=919926.

US Food and Drug Administration. FDA approves Ocaliva for rare, chronic liver disease [media release]. May 31 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503964.htm.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–65.CrossRefPubMed

Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569–72.CrossRefPubMed

Albanis E, Alvarez CE, Pruzansky M, et al. INT-747, a novel FXR activator, reverses hepatic fibrosis and cirrhosis in thioacetamide-induced liver injury in rats [abstract no. 1040]. Hepatology. 2005;42(Suppl 1):605–6.

Verbeke LD, Mannaerts I, Schierwagen R, et al. Obeticholic acid, an FXR agonist, reduces hepatic fibrosis in a rat model of toxic cirrhosis [abstract no. P0445]. J Hepatol. 2015;62(Suppl 2):S479.CrossRef

10.

Nevens F, Andreone P, Mazzella G, et al. An international phase 3 study of the FXR agonist obeticholic acid in PBC patients: effects on markers of cholestasis associated with clinical outcomes and hepatocellular damage [abstract no. 295]. Hepatology. 2014;60(Suppl 4):347A–8A.

11.

Trauner MH, Nevens F, Andreone P, et al. Durable response in the markers of cholestasis through 18 months of open-label long term safety extension study of obeticholic acid in primary biliary cirrhosis [abstract no. Sa1579]. Gastroenterology. 2016;150(4 Suppl 1):S1073–4.CrossRef

12.

Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–61.CrossRefPubMed

13.

Kowdley KV, Shah H, Mason A, et al. Long-term safety and efficacy of obeticholic acid treatment in primary biliary cirrhosis after more than 4 years of treatment [abstract no. 628]. Hepatology. 2015;62(Suppl 1):521A–2A.

14.

Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015;41(1):54–64.CrossRefPubMed

15.

Ratziu V, Sanyal AJ, MacConell L, et al. Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis [abstract no. THU-488]. J Hepatol. 2016;64(Suppl 2):S294–5.

Titel: Obeticholic Acid: First Global Approval
verfasst von: A. Markham
Susan J. Keam
Publikationsdatum: 01.08.2016
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2016
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-016-0616-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Erratum to: Olmutinib: First Global Approval

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

Atezolizumab: First Global Approval

Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

Diclofenac Sodium Bolus Injection (DylojectTM): A Review in Acute Pain Management